Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Update

Sutro Biopharma, Inc. (NASDAQ:STRO) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 528,233 shares, an increase of 30.5% from the December 31st total of 404,777 shares. Based on an average trading volume of 130,917 shares, the short-interest ratio is currently 4.0 days. Approximately 6.6% of the shares of the stock are short sold. Approximately 6.6% of the shares of the stock are short sold. Based on an average trading volume of 130,917 shares, the short-interest ratio is currently 4.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have commented on STRO. Citigroup upgraded shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Wall Street Zen cut Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. HC Wainwright raised their target price on Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Finally, Wedbush reiterated a “neutral” rating and set a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $31.83.

Sutro Biopharma Price Performance

STRO stock opened at $14.83 on Wednesday. The business has a fifty day moving average price of $11.52 and a 200 day moving average price of $9.90. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $21.25. The stock has a market capitalization of $126.20 million, a price-to-earnings ratio of -0.57 and a beta of 1.55.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.25). Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%.The business had revenue of $9.69 million for the quarter, compared to the consensus estimate of $10.14 million. On average, equities analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Velan Capital Investment Management LP grew its holdings in Sutro Biopharma by 2.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after acquiring an additional 60,000 shares during the period. UBS Group AG lifted its stake in shares of Sutro Biopharma by 14.0% in the 3rd quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock valued at $1,602,000 after purchasing an additional 226,955 shares during the period. AQR Capital Management LLC boosted its position in shares of Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Sutro Biopharma during the second quarter worth $492,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Sutro Biopharma in the third quarter valued at about $387,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.